This product page is structured to support compound discovery, product comparison, batch verification, and professional research workflow planning
Getting this right affects dosing accuracy
Evidence boundary The largest Phase 2b trial used oral dosing for 24 weeks and did not show statistically significant weight loss versus placebo
Combining TB-500 with BPC-157 supports tissue migration and blood vessel formation, but through different pathways and mechanisms
Benefits: Powerfully reduces appetite and cravings Enhances feelings of fullness and satisfaction Supports consistent, sustainable fat loss Complements other metabolic and incretin-based compounds To ensure full compliance with MHRA regulations, this product has been withdrawn from public display on our website
It demonstrates powerful anti-inflammatory properties through melanocortin receptor modulation